<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03447483</url>
  </required_header>
  <id_info>
    <org_study_id>17GENE22</org_study_id>
    <nct_id>NCT03447483</nct_id>
  </id_info>
  <brief_title>Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE).</brief_title>
  <acronym>MOTIVATE</acronym>
  <official_title>Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multicentric, prospective cohort study of 150 patients aiming to model
      evolution of toxicity over time in patients with solid tumor and starting first cycle of
      Immune Checkpoint Inhibitor (ICI) treatment.

      The study will be conducted on a population of patients treated with ICI in the context of
      routine care. The follow-up during the treatment period and the clinical, biological and
      radiological assessments will be performed according to the standard of each centre.

      The study data (immune-related adverse events) will be collected during each administration
      of the treatment.

      A questionnaire will be completed by the patient before the treatment administrations.

      Patients will be followed until disease progression or up to 12 months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of toxicities evaluated according to the classification of the Common for Toxicity Criteria for Adverse Events (CTCAE) V4.03</measure>
    <time_frame>12 months by patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to appearance of toxicity</measure>
    <time_frame>12 months by patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients for which treatment was restarted among those who had stopped treatment for the management of an immune-related Adverse Event (irAE)</measure>
    <time_frame>12 months by patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using the QLQ-C30 questionnaire</measure>
    <time_frame>12 months by patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Cohort of patients starting a treatment by ICI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients starting a treatment by ICI</intervention_name>
    <description>Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30) before treatment administration and during the 12 months of treatment period, at the following time points:
every 6 weeks for treatment regimen administered every 2 or 3 weeks
at Weeks 6, 12, 20, 24 for treatment regimen administered every 4 weeks</description>
    <arm_group_label>Cohort of patients starting a treatment by ICI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; or = 18 years old

          2. Patient with a solid tumor whatever the organ

          3. Patient receiving an Immune Checkpoint Inhibitor treatment

          4. Patient starting first cycle of Immune Checkpoint Inhibitor treatment whatever the
             treatment line

          5. Patient affiliated to the french social security system

          6. Patient must provide written informed consent prior to inclusion in the study and any
             study-specific procedure

        Exclusion Criteria:

          1. Patient who must receive a treatment other than Immune Checkpoint Inhibitor

          2. Patient with contraindication to the use of a checkpoint inhibitor (e.g., auto immune
             disorders requiring an immunosuppressive therapy)

          3. Pregnant or breastfeeding women

          4. Any psychological, familial, geographical or sociological condition potentially
             preventing the medical follow-up and/or study procedures

          5. Patient protected by law
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carlos GOMEZ-ROCA</last_name>
    <phone>05 31 15 51 08</phone>
    <email>Gomez-roca.carlos@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Paoli Calmettes (Ipc)</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Renaud SABATIER, MD</last_name>
      <phone>04 91 22 37 89</phone>
      <email>sabatierr@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Regional Du Cancer de Montpellier (Icm)</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diego TOSI, MD</last_name>
      <phone>04 67 61 23 04</phone>
      <email>Diego.Tosi@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delphine LOIRAT, MD</last_name>
      <phone>01 56 24 59 38</phone>
      <email>delphine.loirat@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien MAZIERES, MD</last_name>
      <phone>05 67 77 18 37</phone>
      <email>mazieres.j@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire Du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos GOMEZ-ROCA, MD</last_name>
      <phone>05 31 15 51 08</phone>
      <email>Gomez-roca.carlos@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2018</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumor</keyword>
  <keyword>Immune Checkpoint Inhibitor</keyword>
  <keyword>immune-related Adverse Event</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

